MiR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells

British Journal of Cancer

Volumn 113, Issue 2, 2015, Pages 252-258

  Higashi, T ^a   Hayashi, H ^a   Ishimoto, T ^a   Takeyama, H ^a   Kaida, T ^a   Arima, K ^a   Taki, K ^a   Sakamoto, K ^a   Kuroki, H ^a   Okabe, H ^a   Nitta, H ^a   Hashimoto, D ^a   Chikamoto, A ^a   Beppu, T ^a   Baba, H ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; LET 7B 5P; MICRORNA; MICRORNA 122 3P; MICRORNA 122 5P; MICRORNA 126 3P; MICRORNA 126 5P; MICRORNA 135A 5P; MICRORNA 135B 5P; MICRORNA 149 5P; MICRORNA 155 5P; MICRORNA 182 3P; MICRORNA 192 3P; MICRORNA 192 5P; MICRORNA 194 5P; MICRORNA 196A 5P; MICRORNA 196B 5P; MICRORNA 203A; MICRORNA 208A; MICRORNA 215; MICRORNA 218 1 3P; MICRORNA 34A 3P; MICRORNA 424 5P; MICRORNA 9 3P; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN; PROTEIN KINASE B; TRANSCRIPTIONAL CO ACTIVATOR WITH PDZ BINDING MOTIF; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; CTNNB1 PROTEIN, HUMAN; MIRN92 MICRORNA, HUMAN; SIGNAL PEPTIDE; WWTR1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; CARCINOMA CELL; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; LIVER CELL CARCINOMA; LUCIFERASE ASSAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; GENETICS; LIVER TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION;

BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GENES, TUMOR SUPPRESSOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICRORNAS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84937073773     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.170     Document Type: Article

References (34)

1. Adam R, Frilling A, Elias D, Laurent C, Ramos E, Capussotti L, Poston GJ, Wicherts DA, de Haas RJ, LiverMetSurvey C (2010) Liver resection of colorectal metastases in elderly patients. Br J Surg 97(3): 366-376.
2. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, Amabile MI, Pilozzi E, Patrizii M, Biffoni M, Maugeri-Sacca M, Piccolo S, De Maria R (2014) TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 34(6): 681-690.
3. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q, Hong W (2008) A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 68(8): 2592-2598.
4. Chaulk SG, Lattanzi VJ, Hiemer SE, Fahlman RP, Varelas X (2014) The Hippo pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through Let-7. J Biol Chem 289(4): 1886-1891.
5. Chen CZ, Li L, Lodish HF, Bartel DP (2004) MicroRNAs modulate hematopoietic lineage differentiation. Science 303(5654): 83-86.
6. Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC, Ma L (2012) LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med 18(10): 1511-1517.
7. Croce CM, Calin GA (2005) miRNAs, cancer, and stem cell division. Cell 122(1): 6-7.
8. Fiaschetti G, Abela L, Nonoguchi N, Dubuc AM, Remke M, Boro A, Grunder E, Siler U, Ohgaki H, Taylor MD, Baumgartner M, Shalaby T, Grotzer MA (2014) Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma. Br J Cancer 110(3): 636-647.
9. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822): 1245-1255.
10. Guo Y, Pan Q, Zhang J, Xu X, Liu X, Wang Q, Yi R, Xie X, Yao L, Liu W, Shen L. Functional and Clinical Evidence that TAZ is a Candidate Oncogene in Hepatocellular Carcinoma. J Cell Biochem; e-pub ahead of print 3 February 2015; doi:10. 1002/jcb. 25117.
11. Han SX, Bai E, Jin GH, He CC, Guo XJ, Wang LJ, Li M, Ying X, Zhu Q (2014) Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res 2014: 261365.
12. Huo X, Zhang Q, Liu AM, Tang C, Gong Y, Bian J, Luk JM, Xu Z, Chen J (2013) Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma. Oncol Rep 29(2): 840-846.
13. Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, Kim H (2011) ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9×-mediated suppression of SOX2. Cancer Res 71(9): 3410-3421.
14. Lin CW, Chang YL, Chang YC, Lin JC, Chen CC, Pan SH, Wu CT, Chen HY, Yang SC, Hong TM, Yang PC (2013) MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun 4: 1877.
15. Liu AM, Poon RT, Luk JM (2010a) MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun 394(3): 623-627.
16. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, Dragnev KH, Li H, Direnzo J, Bak M, Freemantle SJ, Kauppinen S, Dmitrovsky E (2010b) MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 120(4): 1298-1309.
17. Ma Y, Yang Y, Wang F, Wei Q, Qin H (2014) Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Int J Cancer 14(1): 96-105.
18. Mitamura T, Watari H, Wang L, Kanno H, Kitagawa M, Hassan MK, Kimura T, Tanino M, Nishihara H, Tanaka S, Sakuragi N (2014) microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway. Mol Cancer 13: 97.
19. Noguchi S, Saito A, Horie M, Mikami Y, Suzuki HI, Morishita Y, Ohshima M, Abiko Y, Mattsson JS, Konig H, Lohr M, Edlund K, Botling J, Micke P, Nagase T (2014) An integrative analysis of the tumorigenic role of TAZ in human non-small cell lung cancer. Clin Cancer Res 20(17): 4660-4672.
20. Qin F, Tian J, Zhou D, Chen L (2013) Mst1 and Mst2 kinases: regulations and diseases. Cell Biosci 3(1): 31.
21. Ramos A, Camargo FD (2012) The Hippo signaling pathway and stem cell biology. Trends Cell Biol 22(7): 339-346.
22. Selcuklu SD, Donoghue MT, Rehmet K, de Souza Gomes M, Fort A, Kovvuru P, Muniyappa MK, Kerin MJ, Enright AJ, Spillane C (2012) MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Bio Chem 287(35): 29516-29528.
23. Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, Fitamant J, Bardeesy N, Camargo FD, Guan KL (2012) YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol 14(12): 1322-1329.
24. Wu S, Huang J, Dong J, Pan D (2003) hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 114(4): 445-456.
25. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115(19): 4576-4585.
26. Yu T, Liu K, Wu Y, Fan J, Chen J, Li C, Yang Q, Wang Z (2013) MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/beta-catenin signaling pathway. Oncogene 33(42): 5017-5027.
27. Yuen HF, McCrudden CM, Huang YH, Tham JM, Zhang X, Zeng Q, Zhang SD, Hong W (2013) TAZ expression as a prognostic indicator in colorectal cancer. PloS one 8(1): e54211.
28. Zawistowski JS, Nakamura K, Parker JS, Granger DA, Golitz BT, Johnson GL (2013) MicroRNA 9-3p targets beta1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition. Mol Cell Biol 33(11): 2260-2274.
29. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL (2012) Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 26(1): 54-68.
30. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, Guan KL (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21(21): 2747-2761.
31. Zheng L, Qi T, Yang D, Qi M, Li D, Xiang X, Huang K, Tong Q (2013) microRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1. PloS One 8(1): e55719.
32. Zhou X, Marian C, Makambi KH, Kosti O, Kallakury BV, Loffredo CA, Zheng YL (2012) MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PloS One 7(6): e39011.
33. Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, Yang X (2011) TAZ is a novel oncogene in non-small cell lung cancer. Oncogene 30(18): 2181-2186.
34. This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4. 0 Unported License